Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy
Regarding STDR, fenofibrate benefit is greatest in type 2 diabetes patients with the lowest baseline HP levels, which may reflect patients more susceptible to oxidative retinal injury. All HP phenotypes benefit from fenofibrate.
Authors
- ANTHONY C. KEECH (ORCID: https://orcid.org/0000-0002-9426-9136)
- Andrzej S. Januszewski (ORCID: https://orcid.org/0000-0003-0995-4524)
- Rachel O’Connell (ORCID: https://orcid.org/0000-0001-5990-8142)
- Habib Francis (ORCID: https://orcid.org/0009-0009-1106-4118)
- Peter G. Colman (ORCID: https://orcid.org/0000-0001-8718-6175)
- Kwok Leung Ong (ORCID: https://orcid.org/0000-0001-7229-7614)
- DAVID R. SULLIVAN (ORCID: https://orcid.org/0000-0003-3085-5627)
- Alicia J. Jenkins (ORCID: https://orcid.org/0000-0003-0583-3717)
- Russell Scott (ORCID: https://orcid.org/0000-0002-2107-6480)
- Abubakar Mangani (ORCID: https://orcid.org/0000-0002-8715-9908)
- Liping Li (ORCID: https://orcid.org/0000-0001-7396-1310)
Institutions
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- Baker Heart and Diabetes Institute (AU)
- Royal Prince Alfred Hospital (AU)
- The Heart Research Institute (AU)
- Christchurch Hospital (NZ)
- National Health and Medical Research Council (AU)
Publication Details
- Journal
- Diabetes Research and Clinical Practice
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1016/j.diabres.2025.112080
- Citations
- 1
- Primary Topic
- Hemoglobin structure and function
- Type
- article
- Field-Weighted Citation Impact
- 1.15